CORT Stock Analysis: Corcept Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 9.834m USD | 12M Return: 31.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 85.4M
EPS Trend: -34.7%
Qual. Beats: -1
Rev. Trend: 97.6%
Qual. Beats: -3
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Corcept Therapeutics Incorporated is a U.S.-based biopharmaceutical company that develops medications targeting severe endocrinologic, oncologic, metabolic, and neurologic disorders. Its flagship commercial product, Korlym, is an oral therapy approved to treat hyperglycemia in adult patients with endogenous Cushings syndrome who also have type 2 diabetes or glucose intolerance and are not candidates for surgery. The company is headquartered in Redwood City, California, and has been incorporated since 1998, trading on NASDAQ under the ticker CORT since its 2004 IPO.
Corcepts pipeline centers on a portfolio of proprietary selective cortisol modulators, including relacorilant (for hypercortisolism), miricorilant (currently in a Phase 1b trial for metabolic dysfunction-associated steatohepatitis, or MASH), and candidates such as nenocorilant and dazucorilant being explored for Lou Gehrigs disease (ALS). As a clinical-stage biopharma with a niche specialty drug franchise, Corcept operates in the GICS Pharmaceuticals sub-industry, where its business model combines revenue from a single approved orphan-indication product with ongoing R&D investment across multiple therapeutic areas driven by cortisol-receptor science.
- Korlym revenue growth sustains quarterly beats
- Relacorilant Phase 3 results in Cushings catalyst
- Generics and Isturisa competition pressure Korlym pricing
| Net Income: 47.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA -6.23 > 1.0 |
| NWC/Revenue: 36.00% < 20% (prev 43.10%; Δ -7.10% < -1%) |
| CFO/TA 0.15 > 3% & CFO 120.1m > Net Income 47.9m |
| Net Debt (-328.5m) to EBITDA (14.2m): -23.21 < 3 |
| Current Ratio: 2.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (104.4m) vs 12m ago -12.84% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 92.59% > 50% (prev 80.98%; Δ 11.61% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.34 (Total Current Assets 426.0m - Total Current Liabilities 149.2m) / Total Assets 814.9m |
| B: 0.75 (Retained Earnings 611.6m / Total Assets 814.9m) |
| C: 0.01 (EBIT TTM 12.1m / Avg Total Assets 830.7m) |
| D: 3.61 (Book Value of Equity 638.0m / Total Liabilities 176.9m) |
| Altman-Z'' = 8.56 = AAA |
| DSRI: 0.41 (Receivables 39.1m/84.4m, Revenue 769.1m/685.4m) |
| GMI: 1.00 (GM 98.43% / 98.25%) |
| AQI: 0.98 (AQ_t 0.46 / AQ_t-1 0.47) |
| SGI: 1.12 (Revenue 769.1m / 685.4m) |
| TATA: -0.09 (NI 47.9m - CFO 120.1m) / TA 814.9m) |
| Beneish M = -3.44 (Cap -4..+1) = AA |
As of July 10, 2026, the stock is trading at USD 93.25 with a total of 1,152,389 shares traded. Over the past week, the price has changed by +5.39%, over one month by +20.34%, over three months by +120.71% and over the past year by +31.54%.
Current recommended Stop Loss: 83.90 (which is 10% or 2.6 ATR below the current price).
Corcept Therapeutics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy CORT.
- StrongBuy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 88 | -5.6% |
P/E Trailing = 261.7429
P/E Forward = 111.1111
P/S = 12.7871
P/B = 15.1793
P/EG = 0.813
Revenue TTM = 769.1m USD
EBIT TTM = 12.1m USD
EBITDA TTM = 14.2m USD
Long Term Debt = 8.01m USD (estimated: total debt 9.64m - short term 1.63m)
Short Term Debt = 1.63m USD (from shortTermDebt, last quarter)
Debt = 9.64m USD (from shortLongTermDebtTotal, last quarter) (leases 9.64m already included)
Net Debt = -328.5m USD (calculated: Debt 9.64m - CCE 338.2m)
Enterprise Value = 9.51b USD (9.83b + Debt 9.64m - CCE 338.2m)
Interest Coverage Ratio = unknown (Ebit TTM 12.1m / Interest Expense TTM 0.0)
EV/FCF = 79.36x (Enterprise Value 9.51b / FCF TTM 119.8m)
FCF Yield = 1.26% (FCF TTM 119.8m / Enterprise Value 9.51b)
FCF Margin = 15.58% (FCF TTM 119.8m / Revenue TTM 769.1m)
Net Margin = 6.23% (Net Income TTM 47.9m / Revenue TTM 769.1m)
Gross Margin = unknown ((Revenue TTM 769.1m - Cost of Revenue TTM 13.5m) / Revenue TTM)
Tobins Q-Ratio = 11.67 (Enterprise Value 9.51b / Total Assets 814.9m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.64m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 9.58m (EBIT 12.1m * (1 - 21.00%))
Current Ratio = 2.86 (Total Current Assets 426.0m / Total Current Liabilities 149.2m)
Debt / Equity = 0.02 (Debt 9.64m / totalStockholderEquity, last quarter 638.0m)
Debt / EBITDA = -23.21 (Net Debt -328.5m / EBITDA 14.2m)
Debt / FCF = -2.74 (Net Debt -328.5m / FCF TTM 119.8m)
Total Stockholder Equity = 638.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.77% (Net Income 47.9m / Total Assets 814.9m)
RoE = 7.50% (Net Income TTM 47.9m / Total Stockholder Equity 638.4m)
RoCE = 1.88% (EBIT 12.1m / Capital Employed (Equity 638.4m + L.T.Debt 8.01m))
RoIC = 1.52% (NOPAT 9.58m / Invested Capital 628.9m)
WACC = 11.60% (E(9.83b)/V(9.84b) * Re(11.61%) + D(9.64m)/V(9.84b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 42.22 | Cagr: -2.63%
[DCF] Terminal Value 62.01% ; FCFF base≈142.7m ; Y1≈125.2m ; Y5≈101.1m
[DCF] Fair Price = 12.95 (EV 1.06b - Net Debt -328.5m = Equity 1.39b / Shares 107.4m; r=11.60% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -34.68 | EPS CAGR: -12.49% | SUE: -1.74 | # QB: -1
Revenue Correlation: 97.62 | Revenue CAGR: 25.74% | SUE: -1.07 | # QB: -3
EPS current Quarter (2026-06-30): EPS=0.04 | Chg30d=-29.42% | Revisions=-17% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.25 | Chg30d=+56.36% | Revisions=+17% | Analysts=3
EPS current Year (2026-12-31): EPS=0.49 | Chg30d=+20.07% | Revisions=+17% | GrowthEPS=-40.6% | GrowthRev=+32.1%
EPS next Year (2027-12-31): EPS=2.50 | Chg30d=+55.16% | Revisions=+17% | GrowthEPS=+411.8% | GrowthRev=+39.2%
[Analyst] Revisions Ratio: +13% (up=7, down=5)